Gates Gives $25 Million for Research on Nutritious Crops
The Bill & Melinda Gates Foundation has given $25 million to help scientists use traditional plant-breeding methods to create more nutritious crops for the developing world.
HarvestPlus, a 10-year research project of a consortium led by the International Food Policy Research Institute (IFPRI) in Washington, D.C., wants to develop rice, wheat, cassava, beans, maize, and other crops enriched in micronutrients such as vitamin A, iron, and zinc. It hopes to avoid the unhappy history of golden rice, an yellow-colored genetically modified crop now in field trials that has faced criticism over everything from patent rights to whether it contains enough vitamin A. "It's not just about science," says Francisco Reifschneider, director of the 16-center Consultative Group on International Agricultural Research (CGIAR), IFPRI's parent.
The project, set to begin in January, marks a departure for CGIAR, which has traditionally focused on productivity gains. The Gates grant brings it halfway to a goal of raising $50 million for the first 4 years.
-JOCELYN KAISER
More SNPs in the Pool
Affymetrix, the Santa Clara, California, gene array company, has greatly expanded the public database of wellcharacterized gene variants. The donation could also contribute to the company's bottom line. The release covers some 120,000 single-nucleotide polymorphisms (SNPs) tested for in 54 volunteers. Although there are nearly 6 million SNPs in public databases, many may be rare and therefore not useful in genetic studies. About half the SNPs that Affymetrix released were already in the public domain but hadn't been studied in large numbers of people.
Researchers hope the newly released SNPs will further efforts to link genetic variation with common diseases. The new SNP information is available on Affymetrix's Web site and on the University of California, Santa Cruz, genome browser. The release isn't all altruism, however. Affymetrix is designing a chip for sale that will test for 100,000 SNPs at once, says Keith Jones, vice president for molecular genetics.
-JENNIFER COUZIN
ScienceScope
Despite the excitement surrounding stem cells' potential to perhaps cure disease or unlock the secrets of development, a fundamental question remains: What, exactly, are stem cells?
In common parlance, they have been defined as cells that can both renew themselves and give rise to more specialized daughter cells. But that is a functional definition, akin to saying that a car is a movable machine on four wheels. Scientists are keen to get under the hood and see which genes drive stem cells' engine of renewal. Although researchers have identified a few genes that seem to play a role, the key molecular switches remain a mystery.
A year ago, two groups reported what they hoped would be a significant step forward. As they described in papers published back to back in Science (18 October 2002, pp. 597 and 601) , groups led by developmental geneticists Douglas Melton of Harvard University and Ihor Lemischka of Princeton University used gene chips to search for a common signal among different kinds of stem cells-a genetic profile that would in essence define the nature of "stemness."
Working independently, both groups compared the gene expression of embryonic stem (ES) cells, hematopoietic or blood-forming stem cells, and neural stem cells. Lemischka's group found 283 genes that were overexpressed in all three of their stem cell populationspresumably part of a genetic characterization of stemness. Melton's group found 230 genes that were overlapping in its populations. But there was a catch. The two sets of genes were almost completely different, sharing only six genes.
A recent study only adds to the confusion. In a Technical Comment published online by Science (see p. 393), Bing Lim and his colleagues at the Genome Institute of Singapore and the Beth Israel Deaconess Medical Center in Boston describe similar experiments with ES cells, neural stem cells, and retinal stem cells. They found 385 genes that were overexpressed in all three cell types. However, only one of those genes is on both Melton's and Lemischka's lists. So what's the problem? "There are a lot of caveats that need to go into interpreting these experiments," says developmental geneticist Leonard Zon of Harvard University. "The cell population you start with makes a huge difference in what is found in a microarray," he says, noting that isolating a pure population of stem cells is notoriously difficult.
Indeed, using gene arrays on some stem cell populations may be a bit like using a millimeter-scale ruler to measure the length of a football field. "One danger here is that the resolution power of the [gene chip] technology might be on the verge of outstripping the resolution of the biological assays" for isolating stem cells, Lemischka says. Any genes expressed by partially differentiated cells in the analyzed population will cloud the gene array results.
Other technical problems, in addition to the purity of the analyzed cells, may confound the work, Lim notes. Key genes might vary their expression over time, he says, or perhaps the sought-after stemness genes are absent from the commercially available chips that all three teams used. In any case, he says, scientists have learned at least one thing: "The stemness gene is not a highly expressed one, if it exists." Both Lemischka and Lim say that despite the lack of overlap between the studies, the results are worth following up. Both groups are working on functional studies of some of their candidate stemness genes, disabling them in populations of stem cells and observing how the cells behave. And even if the specific genes don't overlap, Lemischka says, it's possible that all three studies have identified common signaling pathways that are key to a stem cell's identity-an identity that remains frustratingly elusive.
-GRETCHEN VOGEL 'Stemness' Genes Still Elusive The 80-member college of university rectors, which met last week in Rome, says that the government's refusal to boost budgets has been exacerbated by a proposal to create an Italian Institute of Technology that would drink from the same funding pool.A hiring freeze also has some 1300 researchers waiting to fill posts.And the rectors are unhappy with aspects of a new plan to evaluate the universities themselves."An assessment system implies adequate investment," says Piero Tosi of the University of Siena."A positive evaluation must have a corresponding incentive, otherwise the process becomes sterile."
-SUSAN BIGGIN
Senate Bars Gene Bias
Efforts to protect the public against genetic discrimination took a big step forward this week when the U.S. Senate unanimously passed a proposal prohibiting such practices by employers and health insurers. 
Tracking Hidden DNA Gems
The National Institutes of Health has awarded $12.6 million to help researchers sift through 30 million bases of the DNA sequenced as part of the Human Genome Project. The funding is part of a 3-year, $36 million effort called ENCODE (the ENCyclopedia Of DNA Elements) that is looking for key regulatory and other functional components as well as new genes.
The new program provides for both cooperative agreements to map and study these poorly understood regions of the genome and grants for technology development, such as altering microarrays and other devices to study genes that make multiple proteins. "Our hope is that at the end [of the 3 years] we will have a path toward doing the whole genome," says Elise Feingold of the National Human Genome Research Institute, which manages ENCODE.
-ELIZABETH PENNISI Nir Barzilai knew he'd hit on something when he got a call from the company where he'd sent blood samples for testing. "Were these from rugged athletes?" the company scientist wanted to know. "I told him [the subjects] were 100 years old," recalls Barzilai, who directs the Institute for Aging Research at Albert Einstein School of Medicine in New York City. One sample was from a 103-year-old woman who'd been a heavy smoker since the age of 8. But the blood of nearly all of them-213 Ashkenazi Jews whose average age was 98-brimmed with large lipid particles, something associated with active young adults. But how lipid particle size-as opposed to more common measures such as total cholesterol-influences disease isn't clear. As a result, gerontologists and cardiologists cannot agree on the significance of findings published this week in the Journal of the American Medical Association. Barzilai's team, which was also led by endocrinologist Alan Shuldiner of the University of Maryland School of Medicine in Baltimore, reported that long-lived people have large lipoproteins in their blood and that many of them carry a gene variant that influences cholesterol balance. How the two findings are related isn't clear. Although aging experts question the import of the new results, some cardiologists say the study suggests that a suspected heart disease risk factor may be more worrisome than believed.
Studying why centenarians live as long as they do is no simple task. Worms and flies carry single genes that, when mutated, dramatically prolong life, but nothing that remarkable has been found in humans. Furthermore, a valid control group-critical to establishing unique centenarian traits-isn't easy to come by. "The [other] people born then are dead," says Evan Hadley, associate director of the National Institute on Aging in Bethesda, Maryland.
Barzilai tried to solve this problem by including the centenarians' children, whom he reasoned might have inherited some longevity traits. Seventy-five of the children's spouses and 183 other individuals from the Einstein Aging Study, also all Ashkenazi Jews, agreed to serve as controls. Adding some genetic diversity were data from the Framingham Heart Study, a cohort that's been scrutinized for decades.
Barzilai and his colleagues tested blood samples for levels of total cholesterol and its components of "good" or high density lipoprotein (HDL), "bad" or low density lipoprotein (LDL), and triglycerides. The group also tested concentrations of two proteins involved in cholesterol transport, apolipoprotein A and apolipoprotein B. There was little difference between the centenarian-plus-offspring group and the controls, although some centenarian families had high HDL levels.
As a last resort, Barzilai and colleagues tested the size of HDL and LDL particles, and they hit pay dirt. Eighty percent of centenarians had either large HDL or large LDL particles, or both, compared to 40% and 55% among Ashkenazi controls. Offspring fell in between, and the numbers were lowest in the Framingham cohort. Almost no centenarians had small LDL particles, whereas more than a quarter of controls did.
"The whole issue of lipoprotein in old people is controversial," says Giovanna De Benedictis, a geneticist at the University of Calabria in Italy. She argues that previous centenarian studies have found low levels of total cholesterol-this one did not-and says it's not clear whether the large particles are a cause or effect of longevity, a point echoed by other aging experts.
Barzilai's group also tested for a gene that produces cholesteryl ester transfer protein (CETP). CETP shifts cholesterol molecules from HDL to LDL: Inhibiting CETP helps raise HDL. The protein is "probably the most promising target" for new drugs aiming to control cholesterol and prevent heart disease, says John Kastelein, a cardiologist at Academic Medical Center in Amsterdam. The drug company Pfizer is currently testing a CETP inhibitor in clinical trials. Barzilai's hunch appeared to pay off: 25% of the centenarians
Is Long Life in the Blood?
A G I N G R E S E A R C H Still rocking at 121. Frenchwoman Jeanne Calment, who died in 1997 at the age of 122, shows off a CD she released the year before.
